<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447069</url>
  </required_header>
  <id_info>
    <org_study_id>BTA-HF-01</org_study_id>
    <nct_id>NCT01447069</nct_id>
  </id_info>
  <brief_title>Use of Beta-agonists in Stable Severe Congestive Heart Failure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Salbutamol is effective in the treatment of
      severe heart failure due to ischemic and non- ischemic cardiomyopathy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in plasma level of N-terminal pro-BNP at twelve weeks relative to baseline pro-BNP.</measure>
    <time_frame>12 weeks from baseline pro-BNP assessment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse cardiovascular event: Death, ICD discharge, significant ventricular arrhythmias and hospitalization due to heart failure exacerbation</measure>
    <time_frame>12 weeks after baseline assessment</time_frame>
    <description>Record events of death, ICD discharge and hospitalization due to heart failure exacerbation. Interrogate ICD memory for significant ventricular arrhythmias (ventricular tachycardia and ventricular fibrillation) that did not cause ICD discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class changes</measure>
    <time_frame>12 weeks after baseline assessment</time_frame>
    <description>We will assess NYHA functional class at baseline and after 12 weeks from the beginning of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography parameters changes</measure>
    <time_frame>12 weeks after baseline assessment</time_frame>
    <description>END-SYSTOLIC DIAMETER: _ _ _ MM END-DIASTOLIC DIAMETER: _ _ _ MM LVEF (SIMPSON'S) : _____% Left atrial diameter: ____MM Left atrial area:______cm2 dP/dT: ___32/∆t (mm Hg/msec) E/A: ___ E': ___ cm/s E/E': _____ E wave deceleration time:_____msec Isovolumic relaxation time (IVRT):_____msec
Dimensionless myocardial performance index (MPI) (n&lt;0.4) :
MPI=(TST-ET)/ET TST- total systolic time -from the end of mitral inflow A wave to the beginning of mitral inflow E wave ET - ejection time - time from the beginning to the end of left ventricular outflow tract Doppler envelope</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living with Heart Failure Questionnaire changes</measure>
    <time_frame>12 weeks after baseline assessment</time_frame>
    <description>repeat Minnesota Living with Heart Failure Questionnaire assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-ventricular arrhythmias and electrolytes disturbances</measure>
    <time_frame>baseline, 1 week, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>Plain ECG will be performed at the specified time intervals to detect asymptomatic non-ventricular arrhythmias (atrial fibrillation, atrial flutter, atrial premature beats, etc.) The venous blood will be drawn at the specified time intervals to follow closely after potassium levels (for timely detection of salbutamol induced hypokalemia and to correct accordingly), as well to monitor sodium levels as a prognostic and clinical marker of heart failure exacerbation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <condition>Non-ischemic Cardiomyopathy</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Salbutamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in the study groups will receive the selective β2 agonist, Salbutamol, in addition to their ongoing optimal heart failure therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients in the control group will continue with their regular optimal medical therapy without any intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains &lt;100 bpm</description>
    <arm_group_label>Salbutamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory Patients with a diagnosis of ischemic and non-ischemic cardiomyopathy with
             a measured EF &lt;35%, class III as defined by the NYHA with ICD and who receive optimal
             pharmacological therapy.

        Exclusion Criteria:

          -  Heart Failure class I, II, IV

          -  atrial fibrillation

          -  any significant valvular disease

          -  chronic obstructive pulmonary disease who treated with inhaled β2 agonist

          -  significant kidney disease with eGFR &lt;30%

          -  severe uncontrolled electrolyte abnormalities

          -  prior allergic reaction to Salbutamol

          -  Pregnancy and nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zaza Iakobishvili, MD</last_name>
    <phone>972-3-937100</phone>
    <email>zazai@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tuvia Ben Gal, MD</last_name>
    <phone>972-3-6930</phone>
    <email>bengalt@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin medical center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zaza Iakobishvili, MD</last_name>
      <phone>972-3-9377100</phone>
      <email>zazai@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Tuvia Ben Gal, MD</last_name>
      <phone>972-3-9376930</phone>
      <email>bengalt@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Zaza Iakobishvili, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tuvia Ben Gal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <last_update_submitted>October 2, 2011</last_update_submitted>
  <last_update_submitted_qc>October 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure stage 3</keyword>
  <keyword>beta 2 agonist</keyword>
  <keyword>N-terminal pro-brain natriuretic peptide</keyword>
  <keyword>ejection fraction &lt;35%</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

